Genentech Sustainability Profile
Genentech, a member of the Roche Group, is a pioneering biotechnology company headquartered in South San Francisco, US. Founded in 1976, Genentech has been at the forefront of the biotechnology industry, focusing on the development of innovative medicines for serious medical conditions. The company is renowned for its contributions to oncology, immunology, and neuroscience, with a portfolio that includes groundbreaking therapies such as Herceptin and Avastin. With a commitment to research and development, Genentech has achieved numerous milestones, including the first-ever recombinant DNA product approved by the FDA. Its unique approach to drug development, combining cutting-edge science with a patient-centric philosophy, has solidified its position as a leader in the biopharmaceutical market. Genentech continues to set benchmarks in the industry, driving advancements that improve patient outcomes globally.
DitchCarbon Score
How does Genentech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genentech's score of 40 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genentech's reported carbon emissions
In 2019, Genentech, headquartered in the US, reported total carbon emissions of approximately 187.4 million kg CO2e. This figure includes Scope 1 emissions of about 77.1 million kg CO2e, Scope 2 emissions of approximately 63.4 million kg CO2e, and Scope 3 emissions of around 73.6 million kg CO2e. The company has not publicly disclosed specific reduction targets or initiatives, and there are no SBTi (Science Based Targets initiative) reduction targets noted in their commitments. Genentech's emissions data is cascaded from its parent company, Roche Holding AG, indicating a corporate family relationship that influences its sustainability reporting. The emissions data reflects a comprehensive approach to tracking and managing carbon outputs across all scopes, although specific reduction initiatives have not been detailed in the available information. Overall, Genentech's commitment to addressing climate change is evident through its emissions tracking, but further clarity on reduction strategies and targets would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2004 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,533,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 21,308,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Genentech's Industry?
How Carbon Intensive is Genentech's Location?
Genentech's Scope 3 Categories Breakdown
Genentech's Scope 3 emissions, which increased by 12% last year and increased by approximately 245% since 2004, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 34% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 75% of Scope 3 emissions.
Top Scope 3 Categories
Genentech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genentech has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
